Filing Flows › Generate Biomedicines (GENB) › Q1 2026
Generate Biomedicines (GENB) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 7, 2026
Generate Biomedicines (GENB) reported revenue of $7.2M for the first quarter 2026 (Q1 2026), -18% from a year earlier. Operating margin was -887.5%, net loss $61.7M (854.3% of revenue).
Generate Biomedicines, Q1 2026: revenue $7.2M (-18% year over year), operating margin -887.5%, net loss $61.7M, operating cash flow −$80.4M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $7.2M | — | -18% |
| Operating profit | −$64.1M | — | — |
| Net earnings | −$61.7M | — | — |
| Operating cash flow | −$80.4M | — | — |
What changed
Revenue was $7.2M in Q1 2026, down 18% year over year.
Operating costs exceeded revenue by $64.1M, an operating margin of -887.5%. Total costs grew 25% against a revenue fall of 18%. The fastest-growing cost line was General & admin (+33%). The quarter ended with a net loss of $61.7M. Minority interests bore $268K of it: to shareholders the quarter was a loss of $61.4M.
Operating cash flow was −$80.4M. Non-cash charges added back $3.3M of depreciation and amortization and $6.4M of share-based compensation. Working capital and other items used $28.3M. Capital expenditures of $3.8M exceeded it, leaving free cash flow of −$84.2M.
Questions
What was Generate Biomedicines' revenue in the first quarter 2026?
Generate Biomedicines (GENB) reported revenue of $7.2M for the first quarter 2026 (Q1 2026), -18% from a year earlier.
Was Generate Biomedicines profitable in the first quarter 2026?
Operating loss was $64.1M (-887.5% of revenue) and net loss $61.7M.